文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

甲状腺癌淋巴结比率的预后价值：一项荟萃分析。

The prognostic value of lymph node ratio for thyroid cancer: a meta-analysis.

作者信息

Hu Yue, Wang Zhiyi, Dong Lishuo, Zhang Lu, Xiuyang Li

机构信息

Qi-Huang Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.

College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.

出版信息

Front Oncol. 2024 Feb 7;14:1333094. doi: 10.3389/fonc.2024.1333094. eCollection 2024.

DOI:10.3389/fonc.2024.1333094
PMID:38384804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10879587/
Abstract

BACKGROUND: The prognostic value of lymph node ratio (LNR) has been proved in several cancers. However, the potential of LNR to be a prognostic factor for thyroid cancer has not been validated so far. This article evaluated the prognostic value of LNR for thyroid cancer through a meta-analysis. METHODS: A systematic search was conducted for eligible publications that study the prognostic values of LNR for thyroid cancer in the databases of PubMed, EMBASE, Cochrane, and Web of Science up until October 24, 2023. The quality of the eligible studies was evaluated by The Newcastle-Ottawa Assessment Scale of Cohort Study. The effect measure for meta-analysis was Hazard Ratio (HR). Random effect model was used to calculate the pooled HR and 95% confidence intervals. A sensitivity analysis was applied to assess the stability of the results. Subgroup analysis and a meta-regression were performed to explore the source of heterogeneity. And a funnel plot, Begg's and Egger's tests were used to evaluate publication bias. RESULTS: A total of 15,698 patients with thyroid cancer from 24 eligible studies whose quality were relatively high were included. The pooled HR was 4.74 (95% CI:3.67-6.11; P<0.05) and a moderate heterogeneity was shown (I2 = 40.8%). The results of meta-analysis were stable according to the sensitivity analysis. Similar outcome were shown in subgroup analysis that higher LNR was associated with poorer disease-free survival (DFS). Results from meta-regression indicated that a combination of 5 factors including country, treatment, type of thyroid cancer, year and whether studies control factors in design or analysis were the origin of heterogeneity. CONCLUSION: Higher LNR was correlated to poorer disease free survival in thyroid cancer. LNR could be a potential prognostic indicator for thyroid cancer. More effort should be made to assess the potential of LNR to be included in the risk stratification systems for thyroid cancer. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=477135, identifier CRD42023477135.

摘要

背景：淋巴结比率（LNR）的预后价值已在多种癌症中得到证实。然而，LNR作为甲状腺癌预后因素的潜力迄今尚未得到验证。本文通过荟萃分析评估了LNR对甲状腺癌的预后价值。 方法：在PubMed、EMBASE、Cochrane和Web of Science数据库中进行系统检索，以查找截至2023年10月24日研究LNR对甲状腺癌预后价值的合格出版物。采用队列研究的纽卡斯尔-渥太华评估量表评估合格研究的质量。荟萃分析的效应量为风险比（HR）。采用随机效应模型计算合并HR及95%置信区间。应用敏感性分析评估结果的稳定性。进行亚组分析和荟萃回归以探索异质性来源。并使用漏斗图、Begg检验和Egger检验评估发表偏倚。 结果：共纳入24项质量相对较高的合格研究中的15698例甲状腺癌患者。合并HR为4.74（95%CI：3.67 - 6.11；P<0.05），显示出中度异质性（I² = 40.8%）。敏感性分析表明荟萃分析结果稳定。亚组分析显示类似结果，即较高的LNR与较差的无病生存期（DFS）相关。荟萃回归结果表明，国家、治疗、甲状腺癌类型、年份以及研究在设计或分析中是否控制因素这5个因素的组合是异质性的来源。 结论：较高的LNR与甲状腺癌较差的无病生存期相关。LNR可能是甲状腺癌的一个潜在预后指标。应进一步努力评估LNR纳入甲状腺癌风险分层系统的潜力。 系统评价注册：https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=477135，标识符CRD42023477135 。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/f64d6a6b4ecf/fonc-14-1333094-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/dc67398ee8ad/fonc-14-1333094-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/8adf424aa628/fonc-14-1333094-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/cfa4a917d60f/fonc-14-1333094-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/f12f28ea38eb/fonc-14-1333094-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/9c6cf351e395/fonc-14-1333094-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/191acbeb4b4b/fonc-14-1333094-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/4811811be622/fonc-14-1333094-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/3524d52caf2e/fonc-14-1333094-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/4588ee3abaeb/fonc-14-1333094-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/45c32e8c244f/fonc-14-1333094-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/f64d6a6b4ecf/fonc-14-1333094-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/dc67398ee8ad/fonc-14-1333094-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/8adf424aa628/fonc-14-1333094-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/cfa4a917d60f/fonc-14-1333094-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/f12f28ea38eb/fonc-14-1333094-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/9c6cf351e395/fonc-14-1333094-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/191acbeb4b4b/fonc-14-1333094-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/4811811be622/fonc-14-1333094-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/3524d52caf2e/fonc-14-1333094-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/4588ee3abaeb/fonc-14-1333094-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/45c32e8c244f/fonc-14-1333094-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e550/10879587/f64d6a6b4ecf/fonc-14-1333094-g011.jpg

相似文献

[1]
The prognostic value of lymph node ratio for thyroid cancer: a meta-analysis.

Front Oncol. 2024-2-7

[2]
The prognostic values of lymph node ratio for gynecological cancer: a systematic review and meta-analysis.

Front Oncol. 2024-10-1

[3]
Integrated analysis of the prognostic role of the lymph node ratio in node-positive gastric cancer: A meta-analysis.

Int J Surg. 2018-8-10

[4]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[5]
Intratumoral high endothelial venules in solid tumors: a pooled study.

Front Immunol. 2024

[6]
The Prognostic Significance of Lymph Node Ratio for Esophageal Cancer: A Meta-Analysis.

J Surg Res. 2023-12

[7]
[Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].

Zhonghua Wei Chang Wai Ke Za Zhi. 2021-3-25

[8]
Prognostic value of lymph node micrometastasis in esophageal cancer: A systematic review and meta-analysis.

Front Oncol. 2023-1-4

[9]
Prognostic Role of EGFR/p-EGFR in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis.

Front Oncol. 2021-8-19

[10]
Lymph Node Ratio as a Prognostic Factor in Neck Dissection in Oral Cancer Patients: A Systematic Review and Meta-Analysis.

Cancers (Basel). 2022-9-14

引用本文的文献

[1]
The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline.

Endocrinol Metab (Seoul). 2025-6

[2]
Pathological metastatic lymph node density (ND) predicts early recurrence in papillary thyroid cancer patients after curative resection.

Gland Surg. 2025-5-30

[3]
Long-term efficacy of lobectomy for stage T1 papillary thyroid carcinoma with varying degrees of lymph node metastasis.

Front Endocrinol (Lausanne). 2024

本文引用的文献

[1]
Management of Medullary Thyroid Cancer: Patterns of Recurrence and Outcomes of Reoperative Surgery.

Oncologist. 2023-12-11

[2]
Thyroid cancer.

Lancet. 2023-5-6

[3]
A proposed grading scheme for predicting recurrence in medullary thyroid cancer based on the Ki67 index and metastatic lymph node ratio.

Endocrine. 2023-7

[4]
Targeted therapy and drug resistance in thyroid cancer.

Eur J Med Chem. 2022-8-5

[5]
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020.

Lancet Diabetes Endocrinol. 2022-4

[6]
Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer.

Cancers (Basel). 2021-11-21

[7]
Lymph node yield in the initial central neck dissection (CND) associated with the risk of recurrence in papillary thyroid cancer: A reoperative CND cohort study.

Oral Oncol. 2021-12

[8]
Evaluation of Gender Inequity in Thyroid Cancer Diagnosis: Differences by Sex in US Thyroid Cancer Incidence Compared With a Meta-analysis of Subclinical Thyroid Cancer Rates at Autopsy.

JAMA Intern Med. 2021-10-1

[9]
Risk Factors for Recurrence of Follicular Thyroid Cancer: A Systematic Review.

Thyroid. 2021-10

[10]
Number of Positive Lymph Nodes Is Superior to LNR and LODDS for Predicting the Prognosis of Pancreatic Neuroendocrine Neoplasms.

Front Endocrinol (Lausanne). 2021

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索